Abstracts tagged "interferons and lupus nephritis"

Abstract Number: 641 • 2019 ACR/ARP Annual Meeting
A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Anders Bengtsson ¹, Helena Tyden ¹, Tiffany Pan ², J. Lee Nelson ³ and Christian Lood², ¹Lund University, Lund, Sweden, ²University of Washington, Seattle, ³Fred Hutchinson Cancer Research Center, Seattle
Background/Purpose: Circulating immune complexes (IC) are detectable in a variety of systemic inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), reflecting the…
Abstract Number: 1662 • 2017 ACR/ARHP Annual Meeting
High Type I Interferon Activity Is Associated with Active Class Ⅲ/Ⅳ Lupus Nephritis in European-American Lupus Patients Independent of dsDNA Antibodies
Taro Iwamoto¹, Jessica M. Dorschner², Mark A. Jensen¹, Danielle Vsetecka², Shreyasee Amin³, Ashima Makol⁴, Floranne C. Ernste⁵, Thomas Osborn³, Kevin Moder³, Vaidehi Chowdhary⁶ and Timothy B. Niewold¹, ¹Colton Center for Autoimmunity, New York University, New York, NY, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁶Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Lupus nephritis (LN) is one of the most severe types of organ involvement in systemic lupus erythematosus (SLE), despite the recent advances in immunosuppressive…
Abstract Number: 1754 • 2016 ACR/ARHP Annual Meeting
Double-Negative T (DNT) Cell over-Expressing PD-1 and Helios Is Responsible for Lupus Tissue Injury in Systemic Lupus Erythematosus (SLE): Direct Proof That Increased Interferon Alpha (IFNα) Expression Is Sufficient to Induce SLE in Ifnα-Transgenic Mice
Ken Tsumiyama¹, Chieri Akiyama², Yumi Miyazaki¹, Yasushi Miura², Akira Hashiramoto² and Shunichi Shiozawa¹, ¹Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, ²Department of Biophysics, Kobe University Graduate School of Health Science, Kobe, Japan
Background/Purpose: Previous studies strongly suggest that interferon α (IFNα) may be the principal driver of SLE, where increased IFNα and IFNα-regulated gene transcripts explain many of the immune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].